Centauri Therapeutics Receives an Additional $5.1M from CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials
Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri’s ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X’s total support from 2019 to date to $12.3M.
